Clinical benefits of evolocumab appear less than hoped

Simon B Dimmitt¹, Hans G Stampfer², Jennifer H Martin³, John B Warren⁴

Affiliations

¹ Division of Internal Medicine, University of Western Australia, Crawley, WA 6008, Australia. Electronic address: simondimmitt@gmail.com.
² Division of Psychiatry, University of Western Australia, Crawley, WA 6008, Australia.
³ School of Medicine and Public Health, University of Newcastle, Newcastle, Australia.
⁴ Medicines Assessment, London, UK.

PMID: 29536851
DOI: 10.1016/S0140-6736(18)30530-0

Comment

Clinical benefits of evolocumab appear less than hoped

Simon B Dimmitt et al. Lancet. 2018.

. 2018 Mar 10;391(10124):933-934.

doi: 10.1016/S0140-6736(18)30530-0.

Authors

Simon B Dimmitt¹, Hans G Stampfer², Jennifer H Martin³, John B Warren⁴

Affiliations

¹ Division of Internal Medicine, University of Western Australia, Crawley, WA 6008, Australia. Electronic address: simondimmitt@gmail.com.
² Division of Psychiatry, University of Western Australia, Crawley, WA 6008, Australia.
³ School of Medicine and Public Health, University of Newcastle, Newcastle, Australia.
⁴ Medicines Assessment, London, UK.

PMID: 29536851
DOI: 10.1016/S0140-6736(18)30530-0

No abstract available

PubMed Disclaimer

Comment on

Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial.
Giugliano RP, Pedersen TR, Park JG, De Ferrari GM, Gaciong ZA, Ceska R, Toth K, Gouni-Berthold I, Lopez-Miranda J, Schiele F, Mach F, Ott BR, Kanevsky E, Pineda AL, Somaratne R, Wasserman SM, Keech AC, Sever PS, Sabatine MS; FOURIER Investigators. Giugliano RP, et al. Lancet. 2017 Oct 28;390(10106):1962-1971. doi: 10.1016/S0140-6736(17)32290-0. Epub 2017 Aug 28. Lancet. 2017. PMID: 28859947 Clinical Trial.

Cited by

Monomeric C-Reactive Protein in Atherosclerotic Cardiovascular Disease: Advances and Perspectives.
Melnikov I, Kozlov S, Saburova O, Avtaeva Y, Guria K, Gabbasov Z. Melnikov I, et al. Int J Mol Sci. 2023 Jan 20;24(3):2079. doi: 10.3390/ijms24032079. Int J Mol Sci. 2023. PMID: 36768404 Free PMC article. Review.
The monomeric C-reactive protein level is associated with the increase in carotid plaque number in patients with subclinical carotid atherosclerosis.
Melnikov I, Kozlov S, Pogorelova O, Tripoten M, Khamchieva L, Saburova O, Avtaeva Y, Zvereva M, Matroze E, Kuznetsova T, Prokofieva L, Balakhonova T, Gabbasov Z. Melnikov I, et al. Front Cardiovasc Med. 2022 Jul 22;9:968267. doi: 10.3389/fcvm.2022.968267. eCollection 2022. Front Cardiovasc Med. 2022. PMID: 35935662 Free PMC article.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Other Literature Sources
- scite Smart Citations

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Clinical benefits of evolocumab appear less than hoped

Affiliations

Clinical benefits of evolocumab appear less than hoped

Authors

Affiliations

Comment on

Similar articles

Cited by

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources